Insilico Medicine Secures Multi-Million-Dollar AI Collaboration to Build and Commercialize Biology Foundation Models

Stock News
09/21

Insilico Medicine (03696) has announced a new partnership with a leading foundation model laboratory, securing a collaboration contract valued at up to tens of millions of dollars. The agreement focuses on co-developing, validating, and commercializing a suite of advanced foundation models designed specifically for biological research, leveraging the MMAI Gym training framework.

Under the terms of the deal, both parties will integrate their respective strengths to construct specialized foundation models tailored for generative biology. Insilico Medicine will contribute proprietary datasets covering a range of specialized life science tasks and will conduct closed-loop wet-lab validation on the outputs generated by these foundation models during their training phase.

Furthermore, the collaboration establishes a revenue-sharing model designed to drive global commercialization efforts by tapping into each partner's extensive networks within the biopharmaceutical industry. This strategic alliance underscores a shared commitment to accelerating innovation at the intersection of artificial intelligence and life sciences.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10